Risk factor
Fair trading liquidity
Profitability factor
Undervalued vs peers
About
Heilongjiang ZBD Pharmaceutical Co., Ltd. is a Chinese pharmaceutical firm dedicated to the entire lifecycle of Traditional Chinese Medicine (TCM), from research and development to manufacturing and sales, exclusively within China. Its extensive product portfolio addresses a wide spectrum of health concerns, including conditions related to cardiovascular and cerebrovascular health, respiratory ailments, orthopedic issues, oncology, digestive disorders, anti-infective treatments, neuropsychiatric conditions, and genitourinary problems, among others. Established in 1996, the company maintains its headquarters in Hulin, China.
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced on P/FCF.